Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Melanoma 28Neoplasms 15Carcinoma, Non-Small-Cell Lung 7Multiple Myeloma 6Hematologic Neoplasms 6Neoplasm Metastasis 4Lymphoma 4Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Brain Neoplasms 3Biliary Tract Neoplasms 3Thyroid Neoplasms 2Thyroid Cancer, Papillary 2Skin Neoplasms 2Glioma 2Cholangiocarcinoma 2Bile Duct Neoplasms 2Adenocarcinoma, Follicular 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oligodendroglioma 1Nonseminomatous germ cell tumor 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Myelodysplastic Syndromes 1

Interventions

fludarabine phosphate 87Cyclophosphamide 78Whole-Body Irradiation 59Azacitidine 59fludarabine 56Mycophenolic Acid 56Busulfan 53Tacrolimus 51Peripheral Blood Stem Cell Transplantation 41Melphalan 40Cytarabine 38Antilymphocyte Serum 38Filgrastim 37Granulocyte Colony-Stimulating Factor 33Cyclosporine 33Methotrexate 32Decitabine 32thymoglobulin 22Thiotepa 21Clofarabine 21Cord Blood Stem Cell Transplantation 19Stem Cell Transplantation 16Alemtuzumab 16Sirolimus 15Rituximab 15sargramostim 12Lenalidomide 12Etoposide 11Radiotherapy 10Cyclosporins 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Myelodysplastic Syndromes × trametinib × Clear all
NCT04487106 2025-04-22

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Completed
21 enrolled 14 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡